ZA202006264B - Stable formulations of therapeutic antibody - Google Patents
Stable formulations of therapeutic antibodyInfo
- Publication number
- ZA202006264B ZA202006264B ZA2020/06264A ZA202006264A ZA202006264B ZA 202006264 B ZA202006264 B ZA 202006264B ZA 2020/06264 A ZA2020/06264 A ZA 2020/06264A ZA 202006264 A ZA202006264 A ZA 202006264A ZA 202006264 B ZA202006264 B ZA 202006264B
- Authority
- ZA
- South Africa
- Prior art keywords
- therapeutic antibody
- stable formulations
- formulations
- stable
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841013647 | 2018-04-10 | ||
| PCT/IN2019/050293 WO2019198101A1 (en) | 2018-04-10 | 2019-04-10 | Stable formulations of therapeutic antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202006264B true ZA202006264B (en) | 2022-09-28 |
Family
ID=68164106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/06264A ZA202006264B (en) | 2018-04-10 | 2020-10-08 | Stable formulations of therapeutic antibody |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12433947B2 (enExample) |
| EP (1) | EP3773696A4 (enExample) |
| JP (1) | JP2021521171A (enExample) |
| CN (1) | CN112292146A (enExample) |
| AU (1) | AU2019251453A1 (enExample) |
| BR (1) | BR112020020703A2 (enExample) |
| CO (1) | CO2020013571A2 (enExample) |
| SG (1) | SG11202009876TA (enExample) |
| WO (1) | WO2019198101A1 (enExample) |
| ZA (1) | ZA202006264B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10994011B2 (en) | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| US12024561B2 (en) * | 2018-04-10 | 2024-07-02 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4259192A4 (en) * | 2020-12-09 | 2024-11-20 | Dr. Reddy's Laboratories Limited | STABLE AQUEOUS BUFFER-FREE FORMULATION OF AN INTEGRIN ANTIBODY |
| WO2022253994A1 (en) * | 2021-06-04 | 2022-12-08 | Polpharma Biologics S.A. | Vedolizumab formulation |
| US20250092141A1 (en) * | 2021-12-27 | 2025-03-20 | Polpharma Biologics S.A. | Vedolizumab formulation |
| EP4615502A1 (en) | 2022-11-07 | 2025-09-17 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| CA2690382A1 (en) * | 2007-06-14 | 2008-12-24 | Biogen Idec Ma Inc. | Antibody formulations |
| WO2009080541A1 (en) * | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| UY34054A (es) * | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US20210322549A1 (en) | 2015-07-17 | 2021-10-21 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Natalizumab |
| CA3143167A1 (en) | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Methods of producing an anti-.alpha.4.beta.7 antibody |
-
2019
- 2019-04-10 CN CN201980038006.9A patent/CN112292146A/zh active Pending
- 2019-04-10 AU AU2019251453A patent/AU2019251453A1/en not_active Abandoned
- 2019-04-10 WO PCT/IN2019/050293 patent/WO2019198101A1/en not_active Ceased
- 2019-04-10 EP EP19785714.7A patent/EP3773696A4/en active Pending
- 2019-04-10 US US17/045,406 patent/US12433947B2/en active Active
- 2019-04-10 SG SG11202009876TA patent/SG11202009876TA/en unknown
- 2019-04-10 JP JP2020555466A patent/JP2021521171A/ja active Pending
- 2019-04-10 BR BR112020020703-9A patent/BR112020020703A2/pt not_active IP Right Cessation
-
2020
- 2020-10-08 ZA ZA2020/06264A patent/ZA202006264B/en unknown
- 2020-10-28 CO CONC2020/0013571A patent/CO2020013571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019251453A2 (en) | 2020-12-03 |
| SG11202009876TA (en) | 2020-11-27 |
| EP3773696A4 (en) | 2021-12-29 |
| US20210401982A1 (en) | 2021-12-30 |
| JP2021521171A (ja) | 2021-08-26 |
| CO2020013571A2 (es) | 2021-01-18 |
| BR112020020703A2 (pt) | 2021-01-12 |
| AU2019251453A1 (en) | 2020-11-26 |
| US12433947B2 (en) | 2025-10-07 |
| CN112292146A (zh) | 2021-01-29 |
| EP3773696A1 (en) | 2021-02-17 |
| WO2019198101A1 (en) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202009876TA (en) | Stable formulations of therapeutic antibody | |
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| IL283134A (en) | Alcohol-resistant drug formulations | |
| IL275639A (en) | Formulation for RNA administration | |
| HUE070489T2 (hu) | Lanifibranor deuterizált származékainak terápiás alkalmazása | |
| IL283777A (en) | Methods for formulating antibody drug conjugate compositions | |
| IL278041A (en) | Bezumab formulations with a buffer for use in the treatment of diseases | |
| IL277943A (en) | Stable formulations of anti-CD79B immunoconjugate | |
| IL279622A (en) | Pharmaceutical formulations of masked antibodies | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| IL278151A (en) | Formulations of humanized anti-PD-L1 antibodies | |
| EP3394099A4 (en) | Formulations of Manipulated Anti- IL-10 Antibodies | |
| SG11202104012QA (en) | Antibody formulations | |
| IL272857A (en) | Cofanalisib formulations | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| IL289338B1 (en) | Therapeutic interactions of leucomethylthioninium | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| SG11202010792TA (en) | Improved pharmaceutical formulations | |
| IL283593A (en) | Bernaflam oral preparations | |
| ZA202006262B (en) | Stable antibody formulation | |
| PT3943070T (pt) | Formulações de ação prolongada de bedaquilina | |
| PL4527373T3 (pl) | Nowe preparaty amisulprydu | |
| HK40048083A (en) | Formulations of human anti-pd-l1 antibodies | |
| HK40015441A (en) | Formulations of monoclonal antibodies |